Atropini sulfas

General characteristics. Structure:

Active ingredient: 1 mg of Atropini sulfas in 1 ml of solution.

Pharmacological properties:

Pharmacodynamics. Atropini sulfas concerns to group of anticholinergic medicines. Selectively blocks m-holinoretseptory (to a lesser extent influences N-holinoretseptory), owing to what the last become insensitive to acetylcholine which is formed in the field of the terminations of postganglionic parasympathetic nerves. Atropini sulfas oppresses secretion of salivary and other glands, speeds up reductions of heart, reduces a tone of smooth muscle bodies, is expressed expands pupils (at the same time possibly increase in intraocular pressure). Getting through a blood-brain barrier, atropine excites breath in therapeutic doses. Excites TsNS in high doses.

Pharmacokinetics. After system introduction it is widely distributed in an organism. Gets through a blood-brain barrier. Considerable level in TsNS is reached in 0,5 — 1 h. Linkng with proteins of plasma moderate.

Indications to use:

Drug is appointed at a peptic ulcer of a stomach and a 12-perstny gut, a pylorospasm, cholelithiasis, enterospasms and urinary tract, bronchial asthma, bradycardia as consequences of increase in a tone of a vagus nerve, for reduction of secretion salivary, gastric, bronchial, sometimes - sweat glands, for carrying out X-ray inspection of digestive tract (reduction of a tone and physical activity of bodies). Apply also before an anesthesia and operation and during surgery as the means warning bronkho-and a laryngospasm, reducing the secretion of glands, reflex reactions and side effects caused by excitement of a vagus nerve. Besides, Atropini sulfas — a specific antidote at poisonings with cholinomimetic connections and antikholinesterazny (including organophosphorous) substances.

Route of administration and doses:

At poisonings with cholinomimetics and antikholinesterazny substances of 0,1% solution of Atropini sulfas is entered intravenously, being guided by schemes of antidotal therapy of these intoxications, taking into account use of atropine together with cholinesterase reaktivator.

Subcutaneously, intramusculary and intravenously enter on 0,00025 — 0,0005 — 0,001 g of Atropini sulfas (0,25 — 0,5 — 1,0 ml of 0,1% of solution).

Features of use:

Between receptions of atropine and the antiacid medicines containing A13+ or Sa2+, the interval has to make not less than 1 h. Atropine should not be cancelled sharply since emergence of the symptoms similar to a syndrome of "cancellation" is possible.

Features of use during pregnancy and in the period of a lactation. It is capable to get through a placenta and into breast milk.

Influence on ability to drive the car and potentially dangerous mechanisms. During treatment it is necessary to be careful at control of vehicles and occupation other potentially dangerous types of activity demanding the increased concentration of attention, speed of psychomotor reactions and good sight.

Side effects:

Dryness in a mouth, a mydriasis, accommodation disturbance, tachycardia, difficulty of an urination, dizziness.

Interaction with other medicines:

At use of Atropini sulfas with monoamine oxidase inhibitors there are cardiac arrhythmias, with quinidine, novokainamidy — summation of cholinolytic effect is observed.

At simultaneous use with Dimedrol or isopromethazine effect of atropine amplifies, with nitrates — the probability of increase in intraocular pressure increases.

Under the influence of Octadinum reduction of hyposecretory effect of atropine is possible. Atropine weakens action of m-holinonimetikov and antikholinesterazny means.

Contraindications:

Atropini sulfas is contraindicated at glaucoma, organic lesions of heart and vessels, a prostatauxe, an atony of a bladder, intestines, diseases of kidneys, organism exhaustion. With care it is necessary to appoint at fever, especially at children and elderly people.

Storage conditions:

At a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity. 5 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Solution for injections 1mg/ml in ampoules of 1 ml in packaging No. 10